Free Trial
NASDAQ:CGEN

Compugen (CGEN) Stock Price, News & Analysis

Compugen logo
$1.48 -0.04 (-2.63%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.57 +0.09 (+6.01%)
As of 05/2/2025 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Compugen Stock (NASDAQ:CGEN)

Key Stats

Today's Range
$1.47
$1.56
50-Day Range
$1.18
$1.95
52-Week Range
$1.13
$2.66
Volume
84,129 shs
Average Volume
388,646 shs
Market Capitalization
$132.07 million
P/E Ratio
74.00
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Compugen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

CGEN MarketRank™: 

Compugen scored higher than 36% of companies evaluated by MarketBeat, and ranked 729th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Compugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Compugen has received no research coverage in the past 90 days.

  • Read more about Compugen's stock forecast and price target.
  • Earnings Growth

    Earnings for Compugen are expected to decrease in the coming year, from ($0.03) to ($0.12) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Compugen is 74.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.96.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Compugen is 74.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.69.

  • Price to Book Value per Share Ratio

    Compugen has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Compugen's valuation and earnings.
  • Percentage of Shares Shorted

    2.28% of the float of Compugen has been sold short.
  • Short Interest Ratio / Days to Cover

    Compugen has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Compugen has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Compugen does not currently pay a dividend.

  • Dividend Growth

    Compugen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.28% of the float of Compugen has been sold short.
  • Short Interest Ratio / Days to Cover

    Compugen has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Compugen has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Compugen insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 9.50% of the stock of Compugen is held by insiders.

    • Percentage Held by Institutions

      Only 12.22% of the stock of Compugen is held by institutions.

    • Read more about Compugen's insider trading history.
    Receive CGEN Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

    CGEN Stock News Headlines

    Gold Alert: The Truth About Fort Knox Is Coming
    Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.
    Compugen reports Q4 EPS (7c) vs. 11c last year
    See More Headlines

    CGEN Stock Analysis - Frequently Asked Questions

    Compugen's stock was trading at $1.53 at the start of the year. Since then, CGEN shares have decreased by 3.3% and is now trading at $1.48.
    View the best growth stocks for 2025 here
    .

    Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings results on Tuesday, March, 4th. The biotechnology company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.07 by $0.14. The biotechnology company earned $1.47 million during the quarter, compared to analysts' expectations of $17.47 million. Compugen had a net margin of 2.67% and a trailing twelve-month return on equity of 2.62%.
    Read the conference call transcript
    .

    Compugen's top institutional shareholders include Taylor Frigon Capital Management LLC (1.18%), Rothschild Investment LLC (0.21%) and Calamos Wealth Management LLC (0.03%).

    Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXDW), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL) and

    Company Calendar

    Last Earnings
    3/04/2025
    Today
    5/03/2025
    Next Earnings (Estimated)
    5/19/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Biological products, except diagnostic
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:CGEN
    Employees
    70
    Year Founded
    1993

    Price Target and Rating

    Average Stock Price Target
    $4.00
    High Stock Price Target
    $4.00
    Low Stock Price Target
    $4.00
    Potential Upside/Downside
    +170.3%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    2 Analysts

    Profitability

    Trailing P/E Ratio
    74.00
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-18,750,000.00
    Pretax Margin
    25.27%

    Debt

    Sales & Book Value

    Annual Sales
    $27.86 million
    Price / Cash Flow
    N/A
    Book Value
    $0.73 per share
    Price / Book
    2.03

    Miscellaneous

    Free Float
    80,759,000
    Market Cap
    $132.07 million
    Optionable
    Optionable
    Beta
    3.19

    Social Links

    Beginner's Guide To Retirement Stocks Cover

    Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

    Get This Free Report

    This page (NASDAQ:CGEN) was last updated on 5/3/2025 by MarketBeat.com Staff
    From Our Partners